AstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line treatment for specific endometrial cancer cases. This follows AstraZeneca's strong Q4 earnings, with a significant jump in net profit and revenue. The company attributes this to its focus on innovation.
Humanity faces an existential clash of civilizations, particularly in the Indo-Mediterranean region, the birthplace of major religions. The Gulf Cooperation Council emerges as a stabilizer in the Islamic world, while BRICS offers a platform for the Global South. India's civilizational diplomacy and the GCC's evolving role could shape a more inclusive global order, reflecting the voices of the majority.
Anshul Saigal of Saigal Capital anticipates a breakout in Non-Banking Financial Companies. Regulatory actions have tempered NBFCs, but regulators aim to boost them. Housing finance and general lenders are expected to perform strongly. Manufacturing is experiencing a surge, driven by the Atmanirbhar Bharat initiative and the China plus one strategy. This sector is poised for significant growth and wealth creation.
House Republican leaders are pushing for a Wednesday vote on President Trump's tax and spending cuts package, aiming to capitalise on the Senate's narrow approval. The bill faces internal GOP divisions over Medicaid cuts and fiscal concerns, with leaders pressured to meet Trump's July 4 deadline.
Chirag Muni from Anand Rathi Wealth Limited highlights India's strong macroeconomic foundation, projecting continued GDP growth and easing inflation. He suggests investors maintain a significant equity allocation with a diversified approach, recommending specific mutual funds across market caps for long-term growth, while emphasizing disciplined investing and regular portfolio reviews.
